含去甲氧柔红霉素的强化预处理方案在异基因造血干细胞移植治疗高危恶性血液病中的应用分析-内科学(血液病学)专业论文.docxVIP

华中科技大学硕士学位论文 华 中 科 技 大 学 硕 士 学 位 论 文 4 4 hematopoietic recovery, acute and chronic graft-versus-host disease (GVHD), disease relapse, 2-year overall survival (OS) and disease-free survival (DFS) were evaluated. Data analyses were performed with SPSS 16.0 statistical software. Categorical variables between the two groups were compared by the χ2 test or Fisher’s exact test and continuous variables by the Mann–Whitney U test. All P-values were two-sided and P value 0.05 was considered statistically significant. Results: Between the two groups, there were no significant differences in terms of baseline characteristics, incidence of acute or chronic GVHD or transplant-related mortality (TRM). The tolerance of IDA infusion was good, and IDA-related side effects were moderate. Higher incidences of mild to moderate oropharyngeal mucositis was observed inIDA-BuCy2 group (P=0.015). For the IDA-BuCy2 and BuCy2 groups, relapse rates were 18.9% and 39%, respectively (P=0.030), the 2-year probabilities of overall survival (OS) and disease-free survival (DFS) were 65.3% versus 46.8% (P=0.038), 63.5% versus 43.4% (P=0.025), respectively. Multivariate analysis showed that IDA-BuCy2 regimens and limited chronic GVHD were the only two factors resulting in improved survival and reduced relapse rate. Conclusion: Our retrospective study suggests that IDA intensified BuCy2 conditioning regimen（IDA-BuCy2） may improved survival and reduced relapse rate compared with BuCy2 conditioning regimen for patients with high-risk hematological malignancies. IDA-BuCy2 may substitute BuCy2 as conditioning regimen for patients with high-risk hematological malignancies. The privilege of this intensified regimen should be further confirmed on a larger number of patients and on a longer follow-up duration, and a prospective and randomized study is also needed. Keywords: IDA-BuCy2; allogeneic stem cell transplantation; high-risk leukemia 独创性声明 本人郑重声明，本学位论文是本人在导师指导下进行的研究工作及取得的研究成 果的总结。尽我所知，除文中已经标明引用的内容外，本论